References
- Colombo P, Gazzaniga A, Caramella C, Conte U, La Manna A. In vitro programmable zero-order release drug delivery system. Acta Pharm Technol 1987;33:15–20.
- Konard R, Christ A, Zessin G, Cobet U. The use of ultrasound and penetrometer to characterize the advancement of swelling and eroding fronts in HPMC matrices. Int J Pharm 1998;163:123–131.
- Thomas N, Windle AH. Transport of methanol in poly(methylmethacrylate). Polymer 1978;19:255–265.
- Gao P, Meury H. Swelling of hydroxypropyl methylcellulose matrix tablets. 1. Characterization of swelling using a novel optical imaging method. J Pharm Sci 1996;52:1145–1149.
- Moussa IS, Lenaerts V, Cartilier LH. Image analysis studies of water transport and dimensional changes occurring in the early stages of hydration in cross-linked amylose matrices. J Controlled Release 1998;52:63–70.
- Weisenberg LA, Koenig JL. An NMR imaging study of methanol desorption from partially swollen PMMA rods. Macromolecules 1990;23:2454–2459.
- Rajabi-Siahboomi AR, Bowtell RW, Mansfield P, Henderson A, Davies MC, Melia CD.. Structure and behavior in hydrophilic matrix sustained release dosage forms: 2. NMR-imaging studies of dimensional changes in the gel layer and core of HPMC tablets undergoing hydration. J Controlled Release 1994;31:121–128.
- Mills PJ, Palmstrom CJ, Kramer EJ.. Concentration profiles of non-Fickian diffusants in glassy polymers by Rutherford backscattering spectrometry. J Mater Sci 1986;21:1479–1486.
- Li W, Woldu A, Araba L, Winstead D. Determination of water penetration and drug concentration profiles in HPMC-based matrix tablets by near infrared chemical imaging. J Pharm Sci 2010 (in press).
- Carsten R, Skibsted E, Rasmus B. Near-infrared chemical imaging (NIR-CI) on pharmaceutical solid dosage forms—Comparing common calibration approaches. Journal of Pharmaceutical and Biomedical Analysis 2008;48:554–561.
- Li W, Woldu A, Kelly R, McCool J, Bruce R, Rasmussen H, Cunningham J, Winstead D. Measurement of drug agglomerates in powder blending simulation samples by near infrared chemical imaging. Int J Pharm 2008;350:369–373.
- Lee E, Huang WX, Chen P, Lewis EN, Vivlecchia RV. High throughput analysis of pharmaceutical tablet content uniformity by near-infrared chemical imaging. Spectroscopy 2006;22.
- Takayama K, Nagai T. Novel computer optimization methodology for pharmaceutical formulations investigated by using sustained-release granules of indomethacin. Chem Pharm Bull 1989;37:160–167.
- Singh SK, Dodge J, Durrani MJ, Khan M. Factorial design in the feasibility of producing Microcel MC 101 pellets by extrusion spheronization. Int J Pharm 1995;115:53–60.
- Bouckaert S, Massart DL, Massart B, Rremon JP. Optimization of a granulation procedure for a hydrophilic matrix tablet design. Drug Dev Ind Pharm 1996;22:321–327.
- Huang YB, Tsai YH, Yang WC, Chang JS, Wu PC, Takayama K. Once-daily propranolol extended-release tablet dosage form: formulation design and in vitro/in vivo investigation. Eur J Pharm Biopharm 2004a; 58:607–614.
- Huanga Y, Tsaia Y, Leea S, Changa J, Wu P. Optimization of pH-independent release of nicardipine hydrochloride extended-release matrix tablets using response surface methodology. Int J Pharm 2005;289:87–95.
- Brown W, Knopp RH. The use of niacin. Journal of Clinical Lipidology 2009;3:65–69.
- Guyton JR, Simmons PD. Flushing and other dermatologic adverse events associated with extended-release niacin therapy. Journal of Clinical Lipidology 2009;3:101–108.
- Pieper JA. Understanding niacin formulations. Am J Manag Care 2002;8(12 Suppl):308–314.
- Pieper JA. Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. Am J Health Syst Pharm 2003;1:9–14.
- McKenney JM, Proctor JD, Harris S, Chinchili VM. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;2:672–677.
- Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;21:51–56.
- Nazzal S, El-Malah Y, Khanfar NM. D-Optimal Mixture Design: Optimization of Ternary Matrix Blends for Controlled Zero-Order Drug Release from Oral Dosage Forms. Drug Dev Ind Pharm 2006;32:1207–1218.